Ceremuzynski L, Nartowicz E, Dluzniewski M, Perkowicz J, Czarnecki W, Burduk P, Budaj A, Bednarz B, Chamiec T, Jurgiel R
Department Cardiology, Warsaw Postgraduate Medical School, Poland.
Eur Heart J. 1987 Dec;8 Suppl L:159-63. doi: 10.1093/eurheartj/8.suppl_l.159.
The aim of this study was to investigate the effectiveness of ST 567 in patients suffering from ischaemic heart disease and to compare the effects of this drug with those of propranolol. The study group consisted of 48 male patients, mean age 53, with stable, exercise-induced angina pectoris. After a two-week run-in-placebo period, the patients were randomized to treatment with ST 567 3 X 30 mg (N = 24) and propranolol, 3 X 40 mg (N = 24). The drugs were administered in a double blind fashion during four weeks. Heart rate at rest was decreased by ST 567 from 76 to 65 (P less than 0.005) by propranolol from 76 to 62 (P less than 0.001). Systolic blood pressure was lowered by ST 567 from 131 to 121 (NS) and by propranolol from 133 to 118 (P less than 0.05). Exercise tolerance was increased by ST 567 from 20 X 10(3) to 34 X 10(3) J (P less than 0.05), by propranolol from 26 X 10(3) to 32 X 10(3) J (P less than 0.01) (mean values). Anginal attacks (no. per week) were reduced by ST 567 from 14 to 7 (P less than 0.05) and by propranolol from 14 to 5 (P less than 0.01). Nitroglycerin consumption in no. of tablets per week decreased in ST 567 from 12 to 7 (P less than 0.01), in propranolol from 11 to 4 (P less than 0.0). There were 7 drop outs during treatment with ST 567:2 cases of myocardial infarction, exacerbation of angina in 2 patients, visual disturbances in 2 patients, vertigo in 1 patient. With propranolol we observed worsening of angina in 1 patient, with disturbances in sexual potency in 1.
ST 567 is an effective agent in chronic angina but slightly less effective than propranolol in the dosages studied.
本研究旨在调查ST 567对缺血性心脏病患者的疗效，并将该药的效果与普萘洛尔的效果进行比较。研究组由48名男性患者组成，平均年龄53岁，患有稳定的运动诱发性心绞痛。在为期两周的导入安慰剂期后，患者被随机分为接受ST 567 3×30mg治疗组（N = 24）和普萘洛尔3×40mg治疗组（N = 24）。药物以双盲方式给药四周。静息心率用ST 567治疗后从76降至65（P＜0.005），用普萘洛尔治疗后从76降至62（P＜0.001）。收缩压用ST 567治疗后从131降至121（无统计学意义），用普萘洛尔治疗后从133降至118（P＜0.05）。运动耐量用ST 567治疗后从20×10³焦耳增至34×10³焦耳（P＜0.05），用普萘洛尔治疗后从26×10³焦耳增至32×10³焦耳（P＜0.01）（均值）。心绞痛发作次数（每周）用ST 567治疗后从14次减至7次（P＜0.05），用普萘洛尔治疗后从14次减至5次（P＜0.01）。每周硝酸甘油片消耗量用ST 567治疗后从12片减至7片（P＜0.01），用普萘洛尔治疗后从11片减至4片（P＜0.0）。在ST 567治疗期间有7例退出：2例心肌梗死，2例心绞痛加重，2例视觉障碍，1例眩晕。用普萘洛尔治疗时，我们观察到1例心绞痛加重，1例性功能障碍。
ST 567是治疗慢性心绞痛的有效药物，但在所研究剂量下比普萘洛尔稍欠疗效。
